ENGENEIC
EnGeneIC is a bioscience company, develops and commercializes novel concepts in the targeted delivery of chemotherapeutics for cancer drugs in-vivo. The company’s drug/siRNA delivery vehicles offer a range of choices for optimizing the delivery of clinically meaningful drug and siRNA doses to target cancer cells in-vivo. It serves customers in Australia, Singapore, Japan, and India. The company was incorporated in 2000 and is based in Lane Cove West, Australia.
ENGENEIC
Industry:
Biotechnology Life Science Therapeutics
Founded:
2000-01-01
Address:
Sydney, New South Wales, Australia
Country:
Australia
Website Url:
http://www.engeneic.com
Total Employee:
11+
Status:
Active
Contact:
+61294205844
Total Funding:
16.98 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Domain Not Resolving
Current Employees Featured
William Harris CFO @ EnGeneIC
CFO
2016-01-01
Jennifer A. MacDiarmid Founder, Joint-CEO and Director @ EnGeneIC
Founder, Joint-CEO and Director
Himanshu Brahmbhatt Co-Managing Director and Director @ EnGeneIC
Co-Managing Director and Director
David Seaton COO @ EnGeneIC
COO
Founder
Investors List
Foley Ventures
Foley Ventures investment in Series B - EnGeneIC
Shepherd Kaplan Krochuk
Shepherd Kaplan Krochuk investment in Series B - EnGeneIC
Official Site Inspections
http://www.engeneic.com
- Host name: 66.0.153.160.host.secureserver.net
- IP address: 160.153.0.66
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "EnGeneIC"
EnGeneIC - Crunchbase Company Profile & Funding
EnGeneIC is a bioscience company, develops and commercializes novel concepts in the targeted delivery of chemotherapeutics for cancer drugs in …See details»
EnGeneIC - LinkedIn
EnGeneIC | 2,231 followers on LinkedIn. First-in-class cyto-immunotherapy platform targeting the tumour directly and leveraging the patient's immune system | EngeneIC is a biopharmaceutical ...See details»
EnGeneIC 2025 Company Profile: Valuation, Funding & Investors
EnGeneIC General Information Description. Developer of a clinical-stage biopharmaceutical company designed to target the delivery of chemotherapeutics and functional nucleic acids in …See details»
EnGeneIC - 2025 Company Profile, Funding & Competitors - Tracxn
EnGeneIC is a series B company based in Lane Cove (Australia), founded in 2000 by Himanshu Brahmbhatt and Jennifer MacDiarmid. It operates as a Developer of technology for delivery of …See details»
EnGeneIC Company Profile - Office Locations, Competitors ... - Craft
EnGeneIC has 5 employees across 2 locations and $21.1 m in total funding,. See insights on EnGeneIC including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
EnGeneIC - The Org
EnGeneIC develops and commercializes the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells.See details»
Tech start-ups: cancer biotech EnGeneIC raising $20 million after ...
Nov 13, 2022 Sydney-based biotech EnGeneIC is tapping investors to raise $20 million in bridging funding to buy time until the IPO market reopens and the company can undertake a …See details»
EnGeneIC - Contacts, Employees, Board Members, Advisors
EnGeneIC develops and commercializes the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells. ... Experience the new Crunchbase, powered by AI …See details»
EnGeneIC - Leadership Team - The Org
EnGeneIC. Teams; Leadership Team; Leadership Team. About. EnGeneIC's Leadership Team includes Scott Pattison and 9 others. Team members. Bill Harris. CFO. David Seaton. COO. …See details»
Australian Biotech EnGeneIC Strikes Landmark Deal with Major US …
EnGeneIC’s patented EDV™ (EnGeneIC Dream Vector) nanocell technology also targets and effectively kills cancer cells with minimal toxicity, while stimulating an anti-tumour im-mune …See details»
EnGeneIC Selects Global CDMO BioCina to Advance Their Ground …
Sep 24, 2024 EnGeneIC is a clinical-stage biopharmaceutical company focused on advancing its proprietary EDV™ (EnGeneIC Dream Vector) nanocell technology for oncology and …See details»
EnGeneIC Selects Global CDMO BioCina to Advance Their Ground …
Sep 24, 2024 BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with drug developer …See details»
Is EnGeneIC listed on the ASX? - The Motley Fool Australia
Joint EnGeneIC CEOs, Dr Himanshu Brahmbhatt and Dr Jennifer MacDiarmid, said: "We believe this collaboration will result in an effective vaccine, particularly against mutants of concern, …See details»
EnGeneIC Pty Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Jan 23, 2025 ADELAIDE, South Australia, Sept. 24, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), …See details»
EnGeneIC Pty Ltd. (EnGeneIC Pty Ltd.) - 药物管线_专利_临床试验_ …
ADELAIDE, South Australia, Sept. 24, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a …See details»
EnGeneIC - Crunchbase Company Profile & Funding
EnGeneIC develops and commercializes the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells.See details»
EnGeneIC granted FDA ?Fast-Track? Designation for Novel Armed …
Dec 8, 2023 EnGeneIC contact: Dr. Jennifer MacDiarmid Joint-CEO & Director & EDV technology co-inventor Email: jmacdiarmid@engeneic.com Cell phone: +61-407-953-170; …See details»
Distinguished Oncologist, Professor Daniel Von Hoff joins the ...
Oct 1, 2024 EnGeneIC is a clinical-stage biopharmaceutical company focused on advancing its proprietary EDV (EnGeneIC Dream Vector) nanocell technology for oncology and infectious …See details»
EnGeneIC and Singapore Institute of Advanced Medicine …
Jun 7, 2024 SYDNEY, Australia, June 06, 2024 (GLOBE NEWSWIRE) -- EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted …See details»
EnGeneIC Chooses BioCina as CDMO for Cancer Treatment
Sep 30, 2024 ADELAIDE, South Australia, Sept. 24, 2024 – BioCina Pty Ltd., an international biologics Contract Development and Manufacturing Organization (CDMO), has announced a …See details»